Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SVRA, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 · NCT06431776 | Recruiting |
| Molgramostim Open-label | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 · NCT04544293 | Active not recruiting |
| Vancomycin inhalation powder | MRSA | Phase 3 · NCT03181932 | Completed |
| Antimycobacterial regimen | Mycobacterium Infections, Nontuberculous | Phase 2 · NCT03421743 | Completed |
| Inhaled molgramostim | Mycobacterium Infections, Nontuberculous | Phase 2 · NCT03421743 | Completed |
| Molgramostim nebulizer solution | Mycobacterium Infections, Nontuberculous | Phase 2 · NCT03597347 | Terminated |
| Vancomycin hydrochloride inhalation powder | Cystic Fibrosis | Phase 2 · NCT01746095 | Completed |
| AeroVanc | Healthy | Phase 1 · NCT01537666 | Completed |
| IV vancomycin hydrochloride | Healthy | Phase 1 · NCT01537666 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SVRA holds $129.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.1M/quarter from operations, an estimated runway of 10.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SVRA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Growth Equity Opportunities 17, LLC | 5%+ holder (13D) | 24,471,264 | 11.09% | 2025-11-12 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 20,881,288 | 9.46% | 2025-12-31 |
| Bain Capital Life Sciences Fund II, L.P. | 5%+ holder (13D) | 17,600,621 | 7.98% | 2025-03-25 |
| Dapice Joshua J. | 5%+ holder (13G) | 15,000,000 | 6.80% | 2025-12-31 |
| TCG Crossover GP I, LLC | 5%+ holder (13G) | 12,362,205 | 5.60% | 2025-12-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 10,957,322 | 4.97% | 2025-12-31 |
| David A Ramsay Director |
Insider | 2,533,642 | 1.15% | 2025-12-19 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director · +900,000 options |
Insider | 1,188,050 | 0.54% | 2025-12-14 |
| David L Lowrance Chief Financial Officer · +233,750 options |
Insider | 536,032 | 0.24% | 2026-06-22 |
| Kathleen R. McCabe Chief Legal Officer |
Insider | 519,232 | 0.24% | 2025-12-14 |
| Anne Erickson Chief Business Officer · +300,000 options |
Insider | 371,712 | 0.17% | 2025-12-14 |
| Raymond Dennis Pratt Chief Medical Officer · +280,000 options |
Insider | 340,050 | 0.15% | 2024-12-12 |
Share count 220,623,511 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SVRA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →